HIV, atherosclerosis and inflammation: Implications for treatment

Journal of HIV Therapy

Volumn 14, Issue 3, 2009, Pages 61-68

  William, Chan ^a   Sviridov, Dmitri ^a   Dart, Anthony M ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATORVASTATIN; C REACTIVE PROTEIN; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA DR ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHOLESTEROL TRANSPORT; CORONARY ARTERY BLOOD FLOW; DIET; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EXERCISE; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; LIPODYSTROPHY; MACROPHAGE; METABOLIC DISORDER; MONOCYTE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; REVIEW; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; SMOKING CESSATION; TH1 CELL; TREATMENT INDICATION; UPREGULATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; HIV; HIV INFECTIONS; HUMANS; INFLAMMATION;

EID: 74549131211     PISSN: 14620308     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Hansson GK. Atherosclerosis: An immune disease: the Anitschkov Lecture 2007. Atherosclerosis, 2009, 202, 2-10.
2. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol, 2006, 6, 508-519.
3. Friis-Møller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med, 2007, 356, 1723-1735.
4. SavèsM, Chêne G, Ducimetière et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis, 2003, 37, 292-298.
5. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr, 2009, 51, 268-273.
6. Cotter BR. Epidemiology of HIV cardiac disease. Prog Cardiovasc Dis, 2003, 45, 319-326.
7. Khunnawat C, Mukerji S, Havlichek D Jr et al. Cardiovascular manifestations in human immunodeficiency virus-infected patients. Am J Cardiol, 2008, 102, 635-642.
8. Tabib A, Greenland T, Mercier I et al. Coronary lesions in young HIV-positive subjects at necropsy. Lancet, 1992, 340, 730.
9. Paton P, Tabib A, Loire R et al. Coronary artery lesions and human immunodeficiency virus infection. Res Virol, 1993, 144, 225-231.
10. Glesby MJ. Coronary heart disease in HIV-infected persons. AIDS Read, 2003, 13(4 Suppl), S15-S19.
11. Tabib A, Leroux C, Mornex JF et al. Accelerated coronary atherosclerosis and arteriosclerosis in young humanimmunodeficiency-virus-positive patients. Coron Artery Dis, 2000, 11, 41-46.
12. Varriale P, Saravi G, Hernandez E, Carbon F. Acute myocardial infarction in patients infected with human immunodeficiency virus. Am Heart J, 2004, 147, 55-59.
13. Matetzky S, Domingo M, Kar S et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med, 2003, 163, 457-460.
14. Mujawar Z, Rose H, Morrow MP et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol, 2006, 4, e365.
15. Guaraldi G, Stentarelli C, Zona S et al. Lipodystrophy and antiretroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis, 2009, June 18 (epub ahead of print).
16. Meng Q, Lima JA, Lai H et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J, 2002, 144, 642-648.
17. Kingsley LA, Cuervo-Rojas J, Muñoz A et al. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS, 2008, 22, 1589-1599.
18. Klein D, Hurley LB, Quesenberry CP Jr et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr, 2002, 30, 471-477.
19. Bozzette SA, Ake CF, Tam HK et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med, 2003, 348, 702-710.
20. Friis-Møller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med, 2003, 349, 1993-2003.
21. Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet, 2002, 360, 1747-1748.
22. Kwong GP, Ghani AC, Rode RA et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS, 2006, 20, 1941-1950.
23. El-Sadr WM, Lundgren JD, Neaton JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med, 2006, 355, 2283-2296.
24. Bonnet F, Morlat P, Chêne G et al. Causes of death among HIVinfected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med, 2002, 3, 195-199.
25. Sackoff JE, Hanna DB, Pfeiffer MR, Torrian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med, 2006, 145, 397-406.
26. Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med, 1994, 331, 417-424.
27. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997, 336, 973-979.
28. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000, 342, 836-843.
29. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol, 2006, 26, 2421-2432.
30. Hansson GK, Jonasson L, Lojsthed B et al. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis, 1988, 72, 135-141.
31. Stemme S, Faber B, Holm J et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA, 1995, 92, 3893-3897.
32. Frostegard J, Ulfgren AK, Nyberg P et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis, 1999, 145, 33-43.
33. Pomerantz RJ. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials, 2003, 4, 137-143.
34. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev, 2003, 24, 278-301.
35. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology, 2003, 144, 2195-2200.
36. Hotamisligil GS. Inflammation and metabolic disorders. Nature, 2006, 444, 860-867.
37. Weiss L, Haeffner-Cavaillon, Laude M et al. HIV infection is associated with the spontaneous production of interleukin-1 (IL-1) in vivo and with an abnormal release of IL-1 alpha in vitro. AIDS, 1989, 3, 695-699.
38. Lafeuillade, A, Poizot-Martin I, Quilichini R et al. Increased interleukin-6 production is associated with disease progression in HIV infection. AIDS, 1991, 5, 1139-1140.
39. Noursadeghi M and Miller RF. Clinical value of C-reactive protein measurements in HIV-positive patients. Int J STD AIDS, 2005, 16, 438-441.
40. Guimarães MM, Greco DB, Figueiredo SM et al. High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection. Atherosclerosis, 2008, 201, 434-439.
41. Masiá M, Bernal E, Padilla S et al. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis, 2007, 195, 167-171.
42. Lau B, Sharrett AR, Kingsley LA et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med, 2006, 166, 64-70.
43. Schunkert H, Samani NJ. Elevated C-reactive protein in atherosclerosis: chicken or egg? N Engl J Med, 2008, 359, 1953-1955.
44. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med, 2004, 116(Suppl 6A), 9S-16S.
45. Zacho J, Tybjaerg-Hansen A, Jensen JS et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med, 2008, 359, 1897-1908.
46. Elliott P, Chambers JC, ZhangWet al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA, 2009, 302, 37-48.
47. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med, 2006, 12, 1365-1371.
48. Ancuta, P, Kamat A, Kunstman KJ et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One, 2008. 3, e2516.
49. Almeida CA, Price P, French MA. Immune activation in patients infected with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy. AIDS Res Hum Retroviruses, 2002. 18, 1351-1355.
50. Gascon RL, Narvaez AB, Zhang R et al. Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion. J Acquir Immune Defic Syndr, 2002, 30, 146-153.
51. Lim A, Tan D, Price P et al. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. AIDS, 2007, 21, 1525-1534.
52. Edén A, Price R, Spudich S et al. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis, 2007, 196, 1779-1783.
53. Hunt PW, Martin JN, Sinclair E et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virusinfected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis, 2003, 187, 1534-1543.
54. Hazenberg MD, Stuart JW, Otto SA et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood, 2000, 95, 249-255.
55. Ren Z, Yao Q, Chen C. HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells. Lab Invest, 2002, 82, 245-255.
56. Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis, 2002, 5, 141-151.
57. Paladugu R, Fu W, Conklin BS et al. HIV Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg, 2003, 38, 549-555; discussion 555-556.
58. Martin S, Tesse A, Hugel B et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation, 2004, 109, 1653-1659.
59. 59. Shankar SS, Dubé MP, Gorski JC et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J, 2005, 150, 933.
60. Baliga RS, Liu C, Hoyt DG et al. Vascular endothelial toxicity induced by HIV protease inhibitor: evidence of oxidant-related dysfunction and apoptosis. Cardiovasc Toxicol, 2004, 4, 199-206.
61. Sutliff RL, Dikalov S,Weiss D et al. Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. Am J Physiol Heart Circ Physiol, 2002, 283, H2363-H2370.
62. Wang X, Chai Z, Yao Q, Chen C et al. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr, 2007, 44, 493-499.
63. Dressman J, Kincer J, Matveev SV et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest, 2003, 111, 389-397.
64. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med, 2005, 352, 48-62.
65. Shor-Posner G, Basit A, Lu Y et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med, 1993, 94, 515-519.
66. Hellerstein MK, Grunfeld C, Wu K et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab, 1993, 76, 559-565.
67. Dart AM, Chin-Dusting JP. Lipids and the endothelium. Cardiovasc Res, 1999, 43, 308-322.
68. Purnell JQ, Zambon A, Knopp RH et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS, 2000, 14, 51-57.
69. Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. JAMA, 2003, 289, 2978-2982.
70. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet, 1998, 351, 1881-1883.
71. Krishnaswamy G, Chi DS, Kelley JL et al. The cardiovascular and metabolic complications of HIV infection. Cardiol Rev, 2000, 8, 260-268.
72. Liang JS, Distler O, Cooper DA et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med, 2001, 7, 1327-1331.
73. Bacchetti P, Gripshover B, Grunfeld C et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr, 2005, 40, 121-131.
74. Carr A, Samaras K, Chisholm DJ et al. Abnormal fat distribution and use of protease inhibitors. Lancet, 1998, 351, 1736.
75. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV- 1-infected men starting therapy. AIDS, 2003, 17, 971-979.
76. Dubé MP, Zackin R, Tebas P et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine+lamivudine or didanosine+stavudine combined with nelfinavir, efavirenz, or both: A5005s, a substudy of ACTG 384. Antivir Ther, 2002. 7:L27, Abstract 27.
77. De Lorenzo F, Collot-Teixeira S, Boffito MF et al. Metabolicinflammatory changes, and accelerated atherosclerosis in HIV patients: rationale for preventative measures. Curr Med Chem, 2008, 15, 2991-2999.
78. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS, 2003, 17(Suppl 1), S141-S148.
79. Brinkman K, Smeitink JA, Romijn JA et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet, 1999, 354, 1112-1115.
80. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem, 2000, 275, 41325-41332.
81. Hirosumi J, Tuncman G, Chang L et al. A central role for JNK in obesity and insulin resistance. Nature, 2002, 420, 333-336.
82. Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med, 2005, 165, 1179-1184.
83. Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis, 2001, 32, 130-139.
84. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem, 2000, 275, 20251-20254.
85. Fleischman A, Johnsen S, Systrom DM et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab, 2007, 292, E1666-E1673.
86. Stein JH. Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis, 2003, 45, 293-304.
87. Barbaro G. HIV infection, highly active antiretroviral therapy and the cardiovascular system. Cardiovasc Res, 2003, 60, 87-95.
88. Meroni L, Riva A, Morelli P et al. Increased CD36 expression on circulating monocytes during HIV infection. J Acquir Immune Defic Syndr, 2005, 38, 310-313.
89. Rose H, Hoy J, Woolley I et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis, 2008, 199, 79-86.
90. Bukrinsky M, Sviridov D. Human immunodeficiency virus infection and macrophage cholesterol metabolism. J Leukoc Biol, 2006, 80, 1044-1051.
91. Thomas CM, Smart EJ. How HIV protease inhibitors promote atherosclerotic lesion formation. Curr Opin Lipidol, 2007, 18, 561-565.
92. Fontas E et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis, 2004, 189, 1056-1074.
93. Bergersen BM. Cardiovascular risk in patients with HIV infection: impact of antiretroviral therapy. Drugs, 2006, 66, 1971-1987.
94. Mukhamedova N, Rose H, Cui HL et al. Antiretroviral compounds and cholesterol efflux from macrophages. Atherosclerosis, 2009, March 21 (epub ahead of print).
95. Lipshultz SE, Fisher SD, Lai WW et al. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS, 2003, 17(Suppl 1), S96-S122.
96. Grinspoon SK, Grunfeld C, Kotler DP et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation, 2008, 118, 198-210.
97. Aberg JA, Gallant JE, Anderson J et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis, 2004, 39, 609-629.
98. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 2002, 347, 1557-1565.
99. Koenig W, Löwel H, Baumert J et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation, 2004, 109, 1349-1353.
100. Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med, 2004, 351, 2599-2610.
101. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med, 2001, 344, 1959-1965.
102. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998, 98, 839-844.
103. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 2005, 352, 20-28.
104. Morrow DA, de Lemos JA, Sabatine MS et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation, 2006, 114, 281-288.
105. Ridker PM, Morrow DA, Rose LM et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol, 2005, 45, 1644-1648.
106. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov, 2005, 4, 977-987.
107. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008, 359, 2195-2207.
108. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest, 2002, 110, 285-288.
109. Smith DA, I Galin I. Statin therapy for native and periinterventional coronary heart disease. Curr Mol Med, 2006, 6, 589-602.
110. Stein JH, Merwood MA, Bellehumeur JL et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J, 2004, 147, E18.
111. Hürlimann D, Chenevard R, Ruschitzka F et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart, 2006, 92, 110-112.
112. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
113. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J, 2003, 24, 1601-1610.
114. Dubé MP, Stein JH, Aberg JA et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis, 2003, 37, 613-627.
115. Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis, 2007, 6, 15.
116. Hadigan C, Corcoran C, Basgoz N et al. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA, 2000, 284, 472-477.
117. Fitch KV, Anderson EJ, Hubbard JL et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS, 2006, 20, 1843-1850.
118. Hill A, Sawyer W, Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors onlipid levels. HIV Clin Trials, 2009, 10, 1-12.
119. van der Valk M, Kastelein JJ, Murphy RL et al. Nevirapinecontaining antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS, 2001, 15, 2407-2414.
120. van Leth F, Phanuphak P, Stroes E et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapynaive patients infected with HIV-1. PLoS Med, 2004, 1, e19.
121. Franssen R, Sankatsing RR, Hassink E et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol, 2009, 29, 1336-1341.